.Pharmacolibrary.Drugs.ATC.A.A10BJ06

Information

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus and chronic weight management. It is currently approved for clinical use in both oral and subcutaneous injectable formulations.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy subjects and patients with type 2 diabetes (predominantly adults), after subcutaneous administration.

References

1. Overgaard, RV, et al., & Ingwersen, SH (2019). Population Pharmacokinetics of Semaglutide for Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders 10(2) 649–662. DOI:10.1007/s13300-019-0581-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/30788808

2. Yang, XD, & Yang, YY (2024). Clinical Pharmacokinetics of Semaglutide: A Systematic Review. Drug design, development and therapy 18 2555–2570. DOI:10.2147/DDDT.S470826 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38952487

3. Overgaard, RV, et al., & Kildemoes, RJ (2021). Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clinical pharmacokinetics 60(10) 1335–1348. DOI:10.1007/s40262-021-01025-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/33969456

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)